Cargando…

Asymmetric Membrane Osmotic Capsules for Terbutaline Sulphate

The aim of the present study was to design an asymmetric membrane capsule, an osmotic pump-based drug delivery system of ethyl cellulose for controlled release of terbutaline sulphate. asymmetric membrane capsules contains pore-forming water soluble additive, sorbitol in different concentrations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gobade, N. G., Koland, Marina, Harish, K. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507348/
https://www.ncbi.nlm.nih.gov/pubmed/23204625
http://dx.doi.org/10.4103/0250-474X.102546
_version_ 1782251063935500288
author Gobade, N. G.
Koland, Marina
Harish, K. H.
author_facet Gobade, N. G.
Koland, Marina
Harish, K. H.
author_sort Gobade, N. G.
collection PubMed
description The aim of the present study was to design an asymmetric membrane capsule, an osmotic pump-based drug delivery system of ethyl cellulose for controlled release of terbutaline sulphate. asymmetric membrane capsules contains pore-forming water soluble additive, sorbitol in different concentrations in the capsule shell membrane, which after coming in contact with water, dissolves, resulting in an in situ formation of a microporous structure. The terbutaline sulphate is a β-adrenoreceptor agonist widely used in the treatment of asthma. The oral dosage regimen of terbutaline sulphate is 5 mg twice or thrice daily, the plasma half-life is approximate 3-4 h and it produces GI irritation with extensive first pass metabolism. Hence, terbutaline sulphate was chosen as a model drug with an aim to develop controlled release system. Different formulations of ethyl cellulose were prepared by phase inversion technique using different concentrations of sorbitol as pore forming agent. It was found that the thickness of the prepared asymmetric membrane capsules was increased with increase in concentration of ethyl cellulose and pore forming agent, i.e. sorbitol. The dye release study in water and 10% sodium chloride solution indicates that, the asymmetric membrane capsules follow osmotic principle to release content. The pores formed due to sorbitol were confirmed by microscopic observation of transverse section of capsule membrane. Data of in vitro release study of terbutaline sulphate from asymmetric membrane capsules indicated that, the capsules prepared with 10% and 12.5% of ethyl cellulose and 25% of sorbitol released as much as 97.44% and 76.27% in 12 h, respectively with zero order release rate. Hence asymmetric membrane capsule of 10% ethyl cellulose and 25% of sorbitol is considered as optimum for controlled oral delivery of terbutaline sulphate.
format Online
Article
Text
id pubmed-3507348
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-35073482012-11-30 Asymmetric Membrane Osmotic Capsules for Terbutaline Sulphate Gobade, N. G. Koland, Marina Harish, K. H. Indian J Pharm Sci Short Communication The aim of the present study was to design an asymmetric membrane capsule, an osmotic pump-based drug delivery system of ethyl cellulose for controlled release of terbutaline sulphate. asymmetric membrane capsules contains pore-forming water soluble additive, sorbitol in different concentrations in the capsule shell membrane, which after coming in contact with water, dissolves, resulting in an in situ formation of a microporous structure. The terbutaline sulphate is a β-adrenoreceptor agonist widely used in the treatment of asthma. The oral dosage regimen of terbutaline sulphate is 5 mg twice or thrice daily, the plasma half-life is approximate 3-4 h and it produces GI irritation with extensive first pass metabolism. Hence, terbutaline sulphate was chosen as a model drug with an aim to develop controlled release system. Different formulations of ethyl cellulose were prepared by phase inversion technique using different concentrations of sorbitol as pore forming agent. It was found that the thickness of the prepared asymmetric membrane capsules was increased with increase in concentration of ethyl cellulose and pore forming agent, i.e. sorbitol. The dye release study in water and 10% sodium chloride solution indicates that, the asymmetric membrane capsules follow osmotic principle to release content. The pores formed due to sorbitol were confirmed by microscopic observation of transverse section of capsule membrane. Data of in vitro release study of terbutaline sulphate from asymmetric membrane capsules indicated that, the capsules prepared with 10% and 12.5% of ethyl cellulose and 25% of sorbitol released as much as 97.44% and 76.27% in 12 h, respectively with zero order release rate. Hence asymmetric membrane capsule of 10% ethyl cellulose and 25% of sorbitol is considered as optimum for controlled oral delivery of terbutaline sulphate. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3507348/ /pubmed/23204625 http://dx.doi.org/10.4103/0250-474X.102546 Text en Copyright: © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Gobade, N. G.
Koland, Marina
Harish, K. H.
Asymmetric Membrane Osmotic Capsules for Terbutaline Sulphate
title Asymmetric Membrane Osmotic Capsules for Terbutaline Sulphate
title_full Asymmetric Membrane Osmotic Capsules for Terbutaline Sulphate
title_fullStr Asymmetric Membrane Osmotic Capsules for Terbutaline Sulphate
title_full_unstemmed Asymmetric Membrane Osmotic Capsules for Terbutaline Sulphate
title_short Asymmetric Membrane Osmotic Capsules for Terbutaline Sulphate
title_sort asymmetric membrane osmotic capsules for terbutaline sulphate
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507348/
https://www.ncbi.nlm.nih.gov/pubmed/23204625
http://dx.doi.org/10.4103/0250-474X.102546
work_keys_str_mv AT gobadeng asymmetricmembraneosmoticcapsulesforterbutalinesulphate
AT kolandmarina asymmetricmembraneosmoticcapsulesforterbutalinesulphate
AT harishkh asymmetricmembraneosmoticcapsulesforterbutalinesulphate